Melanoma
NHS England Partners With Scancell to Expand Cancer Vaccine Trial in Melanoma
In the trial, researchers are evaluating Scancell's DNA cancer vaccines SCIB1 and iSCIB1+ alongside immunotherapy.
Servier Licenses Black Diamond Therapeutics' RAF-Targeted Solid Tumor Candidate
In a $780 million deal, Servier is obtaining global rights to develop and commercialize BDTX-4933 in multiple solid tumors with RAS or RAF mutations.
Agilent Technologies Gains Expanded IVDR Certification for PD-L1 CDx
The test has been certified for use in the EU to help guide the treatment of early-stage non-small cell lung cancer and previously untreated advanced melanoma.
Immunocore Outlines Strategic Priorities on Kimmtrak and TCR Therapy Pipeline
The firm is expanding its melanoma portfolio while launching new trials of T-cell receptor therapies in oncology, infectious disease, and autoimmune disease.
UK's NICE Reverses Course on Immunocore's Kimmtrak for Advanced Uveal Melanoma
In recommending Kimmtrak, NICE factored in a new commercial agreement with the sponsor and changed its 2023 negative opinion.